tbuckley/cabot-search huggingface dataset:
Evolution of the Innovative Therapies for Children With Cancer Consortium Trial Portfolio for Drug Development for Children With Cancer
Authors: Francisco Bautista, Jaime Verdú-Amorós, Birgit Geoerger, Alba Rubio-San-Simón, Xavier Paoletti, C. Michel Zwaan, Michela Casanova, Lynley V. Marshall, Fernando Carceller, Francois Doz, Carole Lecinse, Gilles Vassal, Andrew D.J. Pearson, Pamela Kearns, Lucas Moreno
Journal: Journal of Clinical Oncology (2024)

The aim of the Innovative Therapies for Children with Cancer (ITCC) consortium is to improve access to novel therapies for children and adolescents with cancer. The evolution of the ITCC clinical trial portfolio since 2003 was reviewed.
A systematic review and meta-analysis of artificial intelligence versus clinicians for skin cancer diagnosis
Authors: Maria Paz Salinas, Javiera Sepúlveda, Leonel Hidalgo, Dominga Peirano, Macarena Morel, Pablo Uribe, Veronica Rotemberg, Juan Briones, Domingo Mery, Cristian Navarrete-Dechent
Journal: npj Digital Medicine (2024)

Scientific research of artificial intelligence (AI) in dermatology has increased exponentially. The objective of this study was to perform a systematic review and meta-analysis to evaluate the performance of AI algorithms for skin cancer classification in comparison to clinicians with different levels of expertise. Based on PRISMA guidelines, 3 electronic databases (PubMed, Embase, and Cochrane Library) were screened for relevant articles up to August 2022. The quality of the studies was assessed using QUADAS-2. A meta-analysis of sensitivity and specificity was performed for the accuracy of AI and clinicians. Fifty-three studies were included in the systematic review, and 19 met the inclusion criteria for the meta-analysis. Considering all studies and all subgroups of clinicians, we found a sensitivity (Sn) and specificity (Sp) of 87.0% and 77.1% for AI algorithms, respectively, and a Sn of 79.78% and Sp of 73.6% for all clinicians (overall); differences were statistically significant for both Sn and Sp. The difference between AI performance (Sn 92.5%, Sp 66.5%) vs. generalists (Sn 64.6%, Sp 72.8%), was greater, when compared with expert clinicians. Performance between AI algorithms (Sn 86.3%, Sp 78.4%) vs expert dermatologists (Sn 84.2%, Sp 74.4%) was clinically comparable. Limitations of AI algorithms in clinical practice should be considered, and future studies should focus on real-world settings, and towards AI-assistance.
Lifestyle Interventions for Obesity in the Era of GLP-1 Receptor Agonists
Authors: Jamy D. Ard, Kristina H. Lewis, Justin B. Moore
Journal: JAMA (2024)

Pat Hoddinott, MB, BS, PhD; Catriona O'Dolan, PhD; Lisa Macaulay, PhD; Stephan U. Dombrowski, PhD; James Swingler, MSc; Seonaidh Cotton, PhD; Alison Avenell, MD, MB, BS; Abraham M. Getaneh, PhD; Cindy Gray, PhD; Kate Hunt, PhD; Frank Kee, MD; Alice MacLean, PhD; Michelle McKinley, PhD; Claire Torrens, MSc; Katrina Turner, PhD; Marjon van der Pol, PhD; Graeme MacLennan, MSc
An Adaptive Behavioral Intervention for Weight Loss Management
Authors: Bonnie Spring, Angela F. Pfammatter, Laura Scanlan, Elyse Daly, Jean Reading, Sam Battalio, H. Gene McFadden, Don Hedeker, Juned Siddique, Inbal Nahum-Shani
Journal: JAMA (2024)

Lifestyle interventions for weight loss are difficult to implement in clinical practice. Self-managed mobile health implementations without or with added support after unsuccessful weight loss attempts could offer effective population-level obesity management.
Definitions, Etiologies, and Outcomes of Acute on Chronic Liver Failure: A Systematic Review and Meta-analysis
Authors: Arnav Aggarwal, Sagnik Biswas, Umang Arora, Manas Vaishnav, Abhishek Shenoy, Shekhar Swaroop, Ayush Agarwal, Anshuman Elhence, Ramesh Kumar, Amit Goel, None Shalimar
Journal: Clinical Gastroenterology and Hepatology (2024)
Updated Reference Intervals for Alanine Aminotransferase in a Metabolically and Histologically Normal Population
Authors: Jonggi Choi, Chanyoung Jo, Sollip Kim, Mi Ryu, Won-Mook Choi, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young-Suk Lim, Han Chu Lee
Journal: Clinical Gastroenterology and Hepatology (2024)
Nanoparticles targeting OPN loaded with BY1 inhibits vascular restenosis by inducing FTH1-dependent ferroptosis in vascular smooth muscle cells
Authors: Yu Zhang, Bo-yang Zheng, Qian-fan Zhang, Ya-nan Zhao, Qi-ming Yu, Xin Liu, Si-ying Ding, Shuang-shuang Qian, Han Wu, Qian-yu Wu, Yu-han Zhang, Lei Zheng, Xin-hua Zhang, Hao-feng Zhang, Yi-ming Hao, Jing-chao Lu, Lei Wang, Jin-kun Wen, Bin Zheng
Journal: Biomaterials (2024)
Vonoprazan is Efficacious for Treatment of Heartburn in Non-erosive Reflux Disease: A Randomized Trial
Authors: Loren Laine, Stuart Spechler, Rena Yadlapati, Felice Schnoll-Sussman, Neila Smith, Eckhard Leifke, Tom Harris, Barbara Hunt, Ronnie Fass, Philip Katz
Journal: Clinical Gastroenterology and Hepatology (2024)

Potassium-competitive acid blockers have documented efficacy for erosive esophagitis. We performed a randomized trial in United States subjects diagnosed with non-erosive reflux disease of vonoprazan vs placebo for 4 weeks, followed by a 20-week active-treatment extension.
Managing Iatrogenic Aortic Dissection: Insight from 3D-holographic Imaging and CT Computational Fluid Dynamic Simulations
Authors: Tsung-Ying Tsai, Xiao-Jing Guo, Shigetaka Kageyama, Ruth P. Lim, Kaoru Tanaka, Johan De Mey, Mark La Meir, Yoshinobu Onuma, Eric K.W. Poon, Patrick W. Serruys
Journal: Journal of the American College of Cardiology (2024)
Prognostic Value of Microvascular Resistance Reserve After Percutaneous Coronary Intervention in Patients With Myocardial Infarction
Authors: Rob Eerdekens, Mohamed El Farissi, Giovanni Luigi De Maria, Niels van Royen, Marcel van ‘t Veer, Maarten A.H. van Leeuwen, Stephen P. Hoole, Federico Marin, David Carrick, Pim A.L. Tonino, Nico H.J. Pijls, Massimo Fineschi, Keith G. Oldroyd, Colin Berry, Adrian P. Banning, William F. Fearon, Frederik M. Zimmermann
Journal: Journal of the American College of Cardiology (2024)
Rare variants and handedness: spotlight on TUBB4B
Authors: Sebastian Ocklenburg
Journal: Trends in Genetics (2024)

Twin studies suggest that additive genetic effects account for about a quarter of the variance in handedness. Recently, Schijven et al. used exome-wide sequencing to provide evidence for a role of rare protein-coding variants in handedness. These included the gene encoding beta-tubulin, TUBB4B, suggesting that microtubules are relevant for handedness ontogenesis.
Detection of late responders from nonresponders to apremilast by simply measuring pruritus at week 4: Results from a prospective cohort observational study
Authors: Takemichi Fukasawa, Asako Yoshizaki-Ogawa, Atsushi Enomoto, Takashi Yamashita, Kiyoshi Miyagawa, Shinichi Sato, Ayumi Yoshizaki
Journal: Journal of the American Academy of Dermatology (2024)
Global antimicrobial resistance and antibiotic use in COVID-19 patients within health facilities: A systematic review and meta-analysis of aggregated participant data
Authors: Xinyi Yang, Xiying Li, Shengyue Qiu, Chaojie Liu, Shanquan Chen, Haohai Xia, Yingchao Zeng, Lin Shi, Jie Chen, Jinkun Zheng, Shifang Yang, Guobao Tian, Gordon Liu, Lianping Yang
Journal: Journal of Infection (2024)
Ribosomal DNA copy number variation associates with hematological profiles and renal function in the UK Biobank
Authors: Francisco Rodriguez-Algarra, David M. Evans, Vardhman K. Rakyan
Journal: Cell Genomics (2024)

The phenotypic impact of genetic variation of repetitive features in the human genome is currently understudied. One such feature is the multi-copy 47S ribosomal DNA (rDNA) that codes for rRNA components of the ribosome. Here, we present an analysis of rDNA copy number (CN) variation in the UK Biobank (UKB). From the first release of UKB whole-genome sequencing (WGS) data, a discovery analysis in White British individuals reveals that rDNA CN associates with altered counts of specific blood cell subtypes, such as neutrophils, and with the estimated glomerular filtration rate, a marker of kidney function. Similar trends are observed in other ancestries. A range of analyses argue against reverse causality or common confounder effects, and all core results replicate in the second UKB WGS release. Our work demonstrates that rDNA CN is a genetic influence on trait variance in humans.
SARS-CoV-2 infection exacerbates the cellular pathology of Parkinson’s disease in human dopaminergic neurons and a mouse model
Authors: Bina Lee, Ha Nyeoung Choi, Young Hyun Che, Myungjun Ko, Hye Min Seong, Min Gi Jo, Seon-Hee Kim, Chieun Song, Subeen Yoon, Jiwoo Choi, Jeong Hee Kim, Minkyeong Kim, Min Young Lee, Sang Won Park, Hye Jung Kim, Seong Jae Kim, Do Sik Moon, Sun Lee, Jae-Hoon Park, Seung-Geun Yeo, Richard G. Everson, Young Jin Kim, Kyung-Wook Hong, In-Soon Roh, Kwang-Soo Lyoo, Yong Jun Kim, Seung Pil Yun
Journal: Cell Reports Medicine (2024)

While an association between Parkinson's disease (PD) and viral infections has been recognized, the impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on PD progression remains unclear. Here, we demonstrate that SARS-CoV-2 infection heightens the risk of PD using human embryonic stem cell (hESC)-derived dopaminergic (DA) neurons and a human angiotensin-converting enzyme 2 (hACE2) transgenic (Tg) mouse model. Our findings reveal that SARS-CoV-2 infection exacerbates PD susceptibility and cellular toxicity in DA neurons pre-treated with human preformed fibrils (hPFFs). Additionally, nasally delivered SARS-CoV-2 infects DA neurons in hACE2 Tg mice, aggravating the damage initiated by hPFFs. Mice infected with SARS-CoV-2 display persisting neuroinflammation even after the virus is no longer detectable in the brain. A comprehensive analysis suggests that the inflammatory response mediated by astrocytes and microglia could contribute to increased PD susceptibility associated with SARS-CoV-2. These findings advance our understanding of the potential long-term effects of SARS-CoV-2 infection on the progression of PD.
Five-year analysis of neoadjuvant dabrafenib and trametinib for stage III melanoma
Authors: A M Menzies, S N Lo, R P M Saw, M Gonzalez, S Ch'ng, O E Nieweg, K F Shannon, P M Ferguson, J Lee, L Emmett, R Kapoor, R V Rawson, J R Stretch, J F Thompson, A J Spillane, H Rizos, R A Scolyer, G V Long
Journal: Annals of Oncology (2024)
2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS Guideline for the Management of Lower Extremity Peripheral Artery Disease
Authors: Heather L. Gornik, Herbert D. Aronow, Philip P. Goodney, Shipra Arya, Luke Packard Brewster, Lori Byrd, Venita Chandra, Douglas E. Drachman, Jennifer M. Eaves, Jonathan K. Ehrman, John N. Evans, Thomas S.D. Getchius, J. Antonio Gutiérrez, Beau M. Hawkins, Connie N. Hess, Karen J. Ho, W. Schuyler Jones, Esther S.H. Kim, Scott Kinlay, Lee Kirksey, Debra Kohlman-Trigoboff, Chandler A. Long, Amy West Pollak, Saher S. Sabri, Lawrence B. Sadwin, Eric A. Secemsky, Maya Serhal, Mehdi H. Shishehbor, Diane Treat-Jacobson, Luke R. Wilkins
Journal: Journal of the American College of Cardiology (2024)
Ironing out the role of ferroptosis in immunity
Authors: Hannah N. Bell, Brent R. Stockwell, Weiping Zou
Journal: Immunity (2024)

Ferroptosis is a type of regulated cell death that drives the pathophysiology of many diseases. Oxidative stress is detectable in many types of regulated cell death, but only ferroptosis involves lipid peroxidation and iron dependency. Ferroptosis originates and propagates from several organelles, including the mitochondria, endoplasmic reticulum, Golgi, and lysosomes. Recent data have revealed that immune cells can both induce and undergo ferroptosis. A mechanistic understanding of how ferroptosis regulates immunity is critical to understanding how ferroptosis controls immune responses and how this is dysregulated in disease. Translationally, more work is needed to produce ferroptosis-modulating immunotherapeutics. This review focuses on the role of ferroptosis in immune-related diseases, including infection, autoimmune diseases, and cancer. We discuss how ferroptosis is regulated in immunity, how this regulation contributes to disease pathogenesis, and how targeting ferroptosis may lead to novel therapies.
Bladder Outlet Obstruction Relief and Symptom Improvement Following Medical and Surgical Therapies for Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia: A Systematic Review
Authors: Massimiliano Creta, Giorgio I. Russo, Naeem Bhojani, Marcus J. Drake, Christian Gratzke, Benoit Peyronnet, Claus Roehrborn, Kari A.O. Tikkinen, Jean-Nicolas Cornu, Ferdinando Fusco
Journal: European Urology (2024)
Re: Michael Baboudjian, Romain Diamand, Alessandro Uleri, et al. Does Overgrading on Targeted Biopsy of Magnetic Resonance Imaging–visible Lesions in Prostate Cancer Lead to Overtreatment? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2024.02.003
Authors: Hein V. Stroomberg, Klaus Brasso, Andreas Røder
Journal: European Urology (2024)
Noncanonical WNT5A controls the activation of latent TGF-β to drive fibroblast activation and tissue fibrosis
Authors: Thuong Trinh-Minh, Chih-Wei Chen, Cuong Tran Manh, Yi-Nan Li, Honglin Zhu, Xiang Zhou, Debomita Chakraborty, Yun Zhang, Simon Rauber, Clara Dees, Neng-Yu Lin, Delf Kah, Richard Gerum, Christina Bergmann, Alexander Kreuter, Christiane Reuter, Florian Groeber-Becker, Beate Eckes, Oliver Distler, Ben Fabry, Andreas Ramming, Alexandra Schambony, Georg Schett, Jörg Hw Distler
Journal: Journal of Clinical Investigation (2024)

Transforming growth factor β (TGF-β) signaling is a core pathway of fibrosis, but the molecular regulation of the activation of latent TGF-β remains incompletely understood. Here, we demonstrate a crucial role of WNT5A/JNK/ROCK signaling that rapidly coordinates the activation of latent TGF-β in fibrotic diseases. WNT5A was identified as a predominant noncanonical WNT ligand in fibrotic diseases such as systemic sclerosis, sclerodermatous chronic graft-versus-host disease, and idiopathic pulmonary fibrosis, stimulating fibroblast-to-myofibroblast transition and tissue fibrosis by activation of latent TGF-β. The activation of latent TGF-β requires rapid JNK- and ROCK-dependent cytoskeletal rearrangements and integrin αV (ITGAV). Conditional ablation of WNT5A or its downstream targets prevented activation of latent TGF-β, rebalanced TGF-β signaling, and ameliorated experimental fibrosis. We thus uncovered what we believe to be a novel mechanism for the aberrant activation of latent TGF-β in fibrotic diseases and provided evidence for targeting WNT5A/JNK/ROCK signaling in fibrotic diseases as a new therapeutic approach.
Wrecking neutrophil extracellular traps and antagonizing cancer-associated neurotransmitters by interpenetrating network hydrogels prevent postsurgical cancer relapse and metastases
Authors: Hang Zhou, Chunyan Zhu, Qing Zhao, Jinliang Ni, Haipeng Zhang, Guangcan Yang, Jianchao Ge, Chao Fang, Hong Wei, Xianli Zhou, Kun Zhang
Journal: Bioactive Materials (2024)

Tumor-promoting niche after incomplete surgery resection (SR) can lead to more aggressive local progression and distant metastasis with augmented angiogenesis-immunosuppressive tumor microenvironment (TME). Herein, elevated neutrophil extracellular traps (NETs) and cancer-associated neurotransmitters (CANTs, e.g., catecholamines) are firstly identified as two of the dominant inducements. Further, an injectable fibrin-alginate hydrogel with high tissue adhesion has been constructed to specifically co-deliver NETs inhibitor (DNase I)-encapsulated PLGA nanoparticles and an unselective β-adrenergic receptor blocker (propranolol). The two components (i.e., fibrin and alginate) can respond to two triggers (thrombin and Ca2+, respectively) in postoperative bleeding to gelate, shaping into an interpenetrating network (IPN) featuring high strength. The continuous release of DNase I and PR can wreck NETs and antagonize catecholamines to decrease microvessel density, blockade myeloid-derived suppressor cells, secrete various proinflammatory cytokines, potentiate natural killer cell function and hamper cytotoxic T cell exhaustion. The reprogrammed TME significantly suppress locally residual and distant tumors, induce strong immune memory effects and thus inhibit lung metastasis. Thus, targetedly degrading NETs and blocking CANTs enabled by this in-situ IPN-based hydrogel drug depot provides a simple and efficient approach against SR-induced cancer recurrence and metastasis.
Association between oral targeted cancer drug net health benefit, uptake, and spending
Authors: Kelsey S Lau-Min, Yaxin Wu, Shavon Rochester, Justin E Bekelman, Genevieve P Kanter, Kelly D Getz
Journal: JNCI Journal of the National Cancer Institute (2024)

Abstract Background Targeted cancer drugs (TCDs) have revolutionized oncology but vary in clinical benefit and patient out-of-pocket (OOP) costs. The American Society of Clinical Oncology (ASCO) Value Framework uses survival, toxicity, and symptom palliation data to quantify the net health benefit (NHB) of cancer drugs. We evaluated associations between NHB, uptake, and spending on oral TCDs. Methods We conducted a retrospective cohort study of patients aged 18-64 years with an incident oral TCD pharmacy claim in 2012-2020 in a nationwide deidentified commercial claims dataset. TCDs were categorized as having high (&amp;gt;60), medium (40-60), and low (&amp;lt;40) NHB scores. We plotted the uptake of TCDs by NHB category and used standard descriptive statistics to evaluate patient OOP and total spending. Generalized linear models evaluated the relationship between spending and TCD NHB, adjusted for cancer indication. Results We included 8524 patients with incident claims for 8 oral TCDs with 9 first-line indications in advanced melanoma, breast, lung, and pancreatic cancer. Medium- and high-NHB TCDs accounted for most TCD prescriptions. Median OOP spending was $18.78 for the first 28-day TCD supply (interquartile range [IQR] = $0.00-$87.57); 45% of patients paid $0 OOP. Median total spending was $10 118.79 (IQR = $6365.95-$10 600.37) for an incident 28-day TCD supply. Total spending increased $1083.56 for each 10-point increase in NHB score (95% confidence interval = $1050.27 to $1116.84, P &amp;lt; .01 for null hypothesis H0 = $0). Conclusion Low-NHB TCDs were prescribed less frequently than medium- and high-NHB TCDs. Total spending on oral TCDs was high and positively associated with NHB. Commercially insured patients were largely shielded from high OOP spending on oral TCDs.
Sustained‐Release Hydrogen‐Powered Bilateral Microneedles Integrating CD‐MOFs for In Situ Treating Allergic Rhinitis
Authors: Hang Ruan, Meng Long, Jiaqi Li, Di Zhang, Nianping Feng, Yongtai Zhang
Journal: Advanced Healthcare Materials (2024)

Glucocorticoids are widely used for treating allergic rhinitis, but conventional intranasal administration encounters unfavorable nasal cilia clearance and nasal mucosal barrier. Herein, a bilateral microneedle patch is fabricated for delivering cyclodextrin-based metal-organic frameworks (CD-MOF) encapsulating dexamethasone (DXMS) and paeonol (Pae), while NaH particles are mounted on the basal part of each microneedle. By intranasal administration, the microneedles are propelled into the nasal mucosa by NaH-generated hydrogen and then swell to form a hydrogel for sustainedly releasing drugs. The DXMS/Pae combination is demonstrated to be superior to more than the twofold dose of DXMS alone for improving allergic rhinitis in rats. It involves reducing mast cell degranulation and modulating Treg/Th17 cell homeostasis, whereas inhibiting Th1 to Th2 differentiation is associated with regulating the GATA3/T-bet pathway, as well as repairing epithelial barrier function by increasing MUC1 and downregulating periostin. In addition, this delivery system modulates the lipid metabolism of the nasal mucosa. Notably, the newly designed device significantly enhances the drug's therapeutic effect, and NaH-generated hydrogen may have the potential adjunctive therapeutic effect. Collectively, such an emerging microneedle-mediated nasal drug delivery creates a new form for alleviating immune inflammation and contributes a promising solution to reduce clinical glucocorticoid abuse.
Endoscopy-related musculoskeletal injuries to endoscopists: time for an “ergonomic time-out”
Authors: Mihir S. Wagh
Journal: Endoscopy (2024)

Endoscopic procedures are becoming a major part of the practice of gastroenterology, with many gastroenterologists spending a bulk of their clinical time performing endoscopy. As a result, the prevalence of endoscopy-related musculoskeletal pain and injuries among endoscopists is rising, with reports suggesting 29%–89% of endoscopists suffer from such problems [1] [2] [3] [4]. Endoscopy-related injuries (ERIs) result from performing multiple endoscopic procedures daily and the prolonged endoscopy time for complex cases, often involving repetitive movements, awkward posture, and the handling of tedious and cumbersome endoscopic tools. Musculoskeletal pain, carpal tunnel syndrome, and de Quervain's tenosynovitis are a few of the reported injuries related to performing numerous hours of endoscopy over an endoscopist's career. However, most of the available data are from survey studies, where these injuries are likely to be grossly under-reported.
Electrically activated polymetallic nanocrystals for long-term tumor suppression via oxygen-independent ROS generation and electro-immunotherapy
Authors: Manchun Wang, Gui Chen, Ben Hu, Fengling Zhang, Qinqin Xu, Lei Li, Qiye Xi, Jun Liu, Zhiqiang Yu, Peng Cao, Yongxia Wang, Meng Yu
Journal: Journal of Controlled Release (2024)
A computer-aided detection system in the everyday setting of diagnostic, screening, and surveillance colonoscopy: an international, randomized trial
Authors: Michiel H. J. Maas, Timo Rath, Cristiano Spada, Elsa Soons, Nauzer Forbes, Sergey Kashin, Paola Cesaro, Axel Eickhoff, Geoffroy Vanbiervliet, Daniele Salvi, Paul J. Belletrutti, Peter D. Siersema
Journal: Endoscopy (2024)

Background Computer-aided detection (CADe) has been developed to improve detection during colonoscopy. After initial reports of high efficacy, there has been an increasing recognition of variability in the effectiveness of CADe systems. The aim of this study was to evaluate a CADe system in a varied colonoscopy population. Methods A multicenter, randomized trial was conducted at seven hospitals (both university and non-university) in Europe and Canada. Participants referred for diagnostic, non-immunochemical fecal occult blood test (iFOBT) screening, or surveillance colonoscopy were randomized (1:1) to undergo CADe-assisted or conventional colonoscopy by experienced endoscopists. Participants with insufficient bowel preparation were excluded from the analysis. The primary outcome was adenoma detection rate (ADR). Secondary outcomes included adenomas per colonoscopy (APC) and sessile serrated lesions (SSLs) per colonoscopy. Results 581 participants were enrolled, of whom 497 were included in the final analysis: 250 in the CADe arm and 247 in the conventional colonoscopy arm. The indication was surveillance in 202/497 colonoscopies (40.6 %), diagnostic in 199/497 (40.0 %), and non-iFOBT screening in 96/497 (19.3 %). Overall, ADR (38.4 % vs. 37.7 %; P = 0.43) and APC (0.66 vs. 0.66; P = 0.97) were similar between CADe and conventional colonoscopy. SSLs per colonoscopy was increased (0.30 vs. 0.19; P = 0.049) in the CADe arm vs. the conventional colonoscopy arm. Conclusions In this study conducted by experienced endoscopists, CADe did not result in a statistically significant increase in ADR. However, the ADR of our control group substantially surpassed our sample size assumptions, increasing the risk of an underpowered trial.